摘要 |
The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis. |
申请人 |
BIOTHERANOSTICS, INC.;GENERAL HOSPITAL CORPORATION;SGROI, DENNIS;ERLANDER, MARK, G.;ZHANG, YI;SCHNABEL, CATHERINE A |
发明人 |
SGROI, DENNIS;ERLANDER, MARK, G.;ZHANG, YI;SCHNABEL, CATHERINE A |